Parent-of-Origin-Aware Genomic Analysis to Enhance Cascade Testing in Pancreatic Cancer: A Population-Based Study
Abstract
Identifying germline pathogenic variants has therapeutic value for pancreatic ductal adenocarcinoma (PDAC) patients and critical implications for cascade genetic testing in families, the latter being an increasing focus for public health genomic initiatives. We measured cascade testing rates for one hundred consecutive hereditary PDAC probands (March 2014-December 2023) and assessed the potential impact of using a novel technology, Parent-of-Origin-Aware genomic analysis (POAga) to enhance cascade testing. POAga requires a new blood sample and enables variant segregation to the maternal or paternal lineage. Thirteen probands were successfully contacted about POAga and nine provided a research blood sample. Parental origin was determined for all variants, and if applied at the time of diagnosis, would have immediately refined risk estimates for at least 188 relatives. POAga may overcome a major barrier to cascade testing in PDAC by clarifying which side of the family is at risk, improving cascade testing effectiveness and familial cancer prevention strategies.
Related
- PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells
- Contribution of data acquired from spectroscopic, genomic and microbiological analyses to enhance mussels’ quality assessment
- resLens: genomic language models to enhance antibiotic resistance gene detection
- The Relational Cascade Model: a Measurement for Change framework for testing caregiver coaching as upstream mental health promotion
- Multi-Locus Molecular Findings in Pediatric-Onset Inherited Metabolic Disorders: An Eight-Year Series of Outsourced Genomic Testing in Taiwan
BibTeX
@misc{cheng2026parentoforiginaware,
title = {{Parent-of-Origin-Aware Genomic Analysis to Enhance Cascade Testing in Pancreatic Cancer: A Population-Based Study}},
author = {P. T. Cheng and C. Cremin and L. Cordova and V. Akbari and T. Y. Leung and E. Cheung and A. Bedard and Q. Hong and A. Fisic and J. Nuk and M.-J. Asrat and A. Inglis and A. Mindlin and M. O'Loughlin and K. Dixon and K. O'Neill and A. T. Roston and C. Zheng and A. Sharma and Y. Shen and J. Senz and Y. Wang and D. Chan and A. Fok and A. Kahnamelli and S. Bilobram and S. Chan and R. Coope and H.-W. Lee and Y. Zhao and M. Bala and K. Mungall and A. Mungall and R. Moore and D. A. Regier and A. Virani and F. Feldman and J. Laskin and M. Marra and S. Sun and S. Yip and P. M. Lansdorp and S. Jones and D. F. Schaeffer and D. Renouf and K. A. Schrader},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.30.26366356},
url = {https://www.medrxiv.org/content/10.64898/2026.10.30.26366356v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Parent-of-Origin-Aware Genomic Analysis to Enhance Cascade Testing in Pancreatic Cancer: A Population-Based Study
AU - P. T. Cheng
AU - C. Cremin
AU - L. Cordova
AU - V. Akbari
AU - T. Y. Leung
AU - E. Cheung
AU - A. Bedard
AU - Q. Hong
AU - A. Fisic
AU - J. Nuk
AU - M.-J. Asrat
AU - A. Inglis
AU - A. Mindlin
AU - M. O'Loughlin
AU - K. Dixon
AU - K. O'Neill
AU - A. T. Roston
AU - C. Zheng
AU - A. Sharma
AU - Y. Shen
AU - J. Senz
AU - Y. Wang
AU - D. Chan
AU - A. Fok
AU - A. Kahnamelli
AU - S. Bilobram
AU - S. Chan
AU - R. Coope
AU - H.-W. Lee
AU - Y. Zhao
AU - M. Bala
AU - K. Mungall
AU - A. Mungall
AU - R. Moore
AU - D. A. Regier
AU - A. Virani
AU - F. Feldman
AU - J. Laskin
AU - M. Marra
AU - S. Sun
AU - S. Yip
AU - P. M. Lansdorp
AU - S. Jones
AU - D. F. Schaeffer
AU - D. Renouf
AU - K. A. Schrader
PY - 2026
DA - 2026/10/30
PB - medRxiv
DO - 10.64898/2026.10.30.26366356
UR - https://www.medrxiv.org/content/10.64898/2026.10.30.26366356v1
AB - Identifying germline pathogenic variants has therapeutic value for pancreatic ductal adenocarcinoma (PDAC) patients and critical implications for cascade genetic testing in families, the latter being an increasing focus for public health genomic initiatives. We measured cascade testing rates for one hundred consecutive hereditary PDAC probands (March 2014-December 2023) and assessed the potential impact of using a novel technology, Parent-of-Origin-Aware genomic analysis (POAga) to enhance cascade testing. POAga requires a new blood sample and enables variant segregation to the maternal or paternal lineage. Thirteen probands were successfully contacted about POAga and nine provided a research blood sample. Parental origin was determined for all variants, and if applied at the time of diagnosis, would have immediately refined risk estimates for at least 188 relatives. POAga may overcome a major barrier to cascade testing in PDAC by clarifying which side of the family is at risk, improving cascade testing effectiveness and familial cancer prevention strategies.
ER -